Research and Markets has announced the addition of the "Strategic Trends in Private Equity and Venture Capital Funding for Healthcare" report to their offering.

Although the life sciences industry remains an attractive investment area, the healthcare sector has seen a decline in venture investments, particularly for early-stage investments, as pricing pressures, stringent regulations, rising development costs, reimbursement issues, and declining R&D productivity have proved significant barriers.

The continued decline in R&D productivity is one of the most important challenges the healthcare industry is facing at a global level. Blockbuster therapies, for example, have become increasingly rare, and many drugs continue to face reimbursement challenges in key markets, resulting in declining revenues for companies.

The accumulating evidence of the decline in R&D productivity adds to the uncertainty associated with innovation in the healthcare industry, which in turn reduces the attractiveness of the field for investment.

Despite this, a recent surge in the approval of innovative drugs, coupled with reports of companies having been more successful in the final stages of clinical testing, seems to point towards a brighter future in this regard. Indeed, the number of new molecular entities launched globally in 2014 reached a 17-year high of 46.

If investments from private equity and venture capital (VC) firms in the healthcare industry continue to decrease significantly, it could have serious and wide-ranging consequences not just in the healthcare sector, but in wider economies. Fewer treatment options, a sharp decline in innovation, and significant financial constraints for companies in the sector could result in job losses, important projects being abandoned, and company relocations or complete shutdowns.

Companies Mentioned:

  • Adaptimmune Therapeutics
  • Aimmune Therapeutics
  • Apax Partners
  • Axovant Sciences
  • Bain Capital Private Equity
  • Blueprint Medicines
  • Flagship Ventures
  • Global Blood Therapeutics
  • KKR & Co
  • Kleiner Perkins Caufield & Byers
  • (10+ Others)

Key Topics Covered:

1 Table of Contents

2 Introduction

3 Global Trends in Private Equity and Venture Capital Investments in the Healthcare Industry

4 US Private Equity and Venture Capital Industry Dynamics

5 Equity Offerings in the Healthcare Sector, Value and Volume, 2006-2015

6 Private Equity Firms, Company Drill-Downs

7 Venture Capital Firms, Company Drill-Downs

8 Future Outlook

9 Conclusions

For more information about this report visit http://www.researchandmarkets.com/research/grz9sm/strategic_trends

Research and MarketsLaura Wood, Senior Managerpress@researchandmarkets.comFor E.S.T Office Hours Call 1-917-300-0470For U.S./CAN Toll Free Call 1-800-526-8630For GMT Office Hours Call +353-1-416-8900U.S. Fax: 646-607-1907Fax (outside U.S.): +353-1-481-1716Related Topics: Venture Capital, Private Equity